Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

GHK vs Klow

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

GHK and Klow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

GHK

Preclinical + Cosmetic

Klow

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

GHK Klow
Class Matrikine tripeptide; signaling/reparative Four-component regenerative blend (Glow + KPV anti-inflammatory)
Drug class Tissue Repair Tissue Repair
Mechanism Modulates expression of hundreds of genes related to tissue repair; copper transport Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm.
Route Topical / SC SC injection
Half-life Minutes (plasma) Composite: hours to days per component (TB-500 longest)
Dosage (research) 1-5 mg daily topical/SC (research) Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose
Evidence tier Preclinical + Cosmetic Anecdotal
Research depth 163 indexed (PubMed 145 · CT 1 · EPMC 17) —
Availability Research Compounding Restricted
Reported risks Less bioavailable than GHK-Cu; limited injectable human trials No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick GHK or Klow?

GHK and Klow share the matrikine class and carry roughly equivalent evidence (Preclinical + Cosmetic / Anecdotal). On the catalogued data layer GHK has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; GHK's evidence base is currently denser.

What is the difference between GHK and Klow?

GHK is classed as Matrikine tripeptide; signaling/reparative; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: GHK, Modulates expression of hundreds of genes related to tissue repair; copper transport; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: GHK, Minutes (plasma); Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: GHK, Topical / SC; Klow, SC injection.

Which has stronger evidence, GHK or Klow?

Klow has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK is graded Preclinical + Cosmetic, with 8 cited sources on its reference page and 163 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.

Which is more accessible, GHK or Klow?

Neither GHK nor Klow is an FDA-approved drug. Catalog status: GHK, Research; Klow, Compounding Restricted.

Are GHK and Klow ever combined?

GHK and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…